Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO) from its SEC filings: 2025 revenue $10.0 million (+100% vs the year before), net margin -3777%, free cash flow -$172.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $10.0 million |
| Revenue growth | +100% |
| Net income | -$377.7 million |
| Net margin | -3777.4% |
| Free cash flow | -$172.4 million |
| Diluted EPS | $-8.44 |
| Cash | $196.6 million |
| Long-term debt | $78.6 million |
| Share count, 1 year | +55% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.